The theme for this year’s DIA 2017 Annual Meeting was “Driving Insights to Action.” DIA hosted more than 7,000 professionals in the pharmaceutical, biotechnology, and medical device communities from more than 50 countries around the globe. Given the broad multidisciplinary nature of the attendees, PRA Health Sciences wanted to gather actionable insights from this heterogeneous group. We wanted to know their thoughts on the state of innovation and technology in the life-sciences industry and what would have the greatest impact on this industry in the near term.
Our collaborative, cross-functional team develops tailored, cost-effective services to meet the unique needs of biosimilars clinical development.
Biosimilars Newsletter Volume 5, January 2015
Welcome to the fifth edition of Biosimilars Newsletter, a quarterly publication dedicated to keeping you updated on current biosimilars news,…
Biobetters: Challenges and Opportunities
Please join PRA Health Sciences' Dr. Hazel Gorham as she talks with PharmaVoice about what a biobetter is, how biobetters compare to biosimilars,…